Transthyretin, a New Cryptic Protease
2004; Elsevier BV; Volume: 279; Issue: 20 Linguagem: Inglês
10.1074/jbc.m402212200
ISSN1083-351X
AutoresMárcia A. Liz, Carlos Faro, Maria João Saraiva, Mónica Mendes Sousa,
Tópico(s)Protein Kinase Regulation and GTPase Signaling
ResumoTransthyretin (TTR) is a plasma homotetrameric protein that acts physiologically as a transporter of thyroxine (T4) and retinol, in the latter case through binding to retinol-binding protein (RBP). A fraction of plasma TTR is carried in high density lipoproteins by binding to apolipoprotein AI (apoA-I). We further investigated the nature of the TTR-apoA-I interaction and found that TTR from different sources (recombinant and plasmatic) is able to process proteolytically apoA-I, cleaving its C terminus after Phe-225. TTR-mediated proteolysis was inhibited by serine protease inhibitors (phenylmethanesulfonyl fluoride, Pefabloc, diisopropyl fluorophosphate, chymostatin, and Nα-p-tosyl-l-phenylala-nine-chloromethyl ketone), suggesting a chymotrypsin-like activity. A fluorogenic substrate corresponding to an apoA-I fragment encompassing amino acid residues 223-228 (Abz-ESFKVS-EDDnp) was used to characterize the catalytic activity of TTR, including optimum reaction conditions (37 °C and pH 6.8) and catalytic constant (Km = 29 μm); when complexed with RBP, TTR activity was lost, whereas when complexed with T4, only a slight decrease was observed. Cell lines expressing TTR were able to degrade Abz-ESFKVS-EDDnp 2-fold more efficiently than control cells lacking TTR expression; this effect was reversed by the presence of RBP in cell culture media, therefore proving a TTR-specific proteolytic activity. TTR can act as a novel plasma cryptic protease and might have a new, potentially important role under physiological and/or pathological conditions. Transthyretin (TTR) is a plasma homotetrameric protein that acts physiologically as a transporter of thyroxine (T4) and retinol, in the latter case through binding to retinol-binding protein (RBP). A fraction of plasma TTR is carried in high density lipoproteins by binding to apolipoprotein AI (apoA-I). We further investigated the nature of the TTR-apoA-I interaction and found that TTR from different sources (recombinant and plasmatic) is able to process proteolytically apoA-I, cleaving its C terminus after Phe-225. TTR-mediated proteolysis was inhibited by serine protease inhibitors (phenylmethanesulfonyl fluoride, Pefabloc, diisopropyl fluorophosphate, chymostatin, and Nα-p-tosyl-l-phenylala-nine-chloromethyl ketone), suggesting a chymotrypsin-like activity. A fluorogenic substrate corresponding to an apoA-I fragment encompassing amino acid residues 223-228 (Abz-ESFKVS-EDDnp) was used to characterize the catalytic activity of TTR, including optimum reaction conditions (37 °C and pH 6.8) and catalytic constant (Km = 29 μm); when complexed with RBP, TTR activity was lost, whereas when complexed with T4, only a slight decrease was observed. Cell lines expressing TTR were able to degrade Abz-ESFKVS-EDDnp 2-fold more efficiently than control cells lacking TTR expression; this effect was reversed by the presence of RBP in cell culture media, therefore proving a TTR-specific proteolytic activity. TTR can act as a novel plasma cryptic protease and might have a new, potentially important role under physiological and/or pathological conditions. Transthyretin (TTR) 1The abbreviations used are: TTR, transthyretin; apoA-I, apolipoprotein AI; ATTR, transthyretin-related amyloidosis, DFP, diisopropyl fluorophosphate; HDL, high-density lipoprotein; HPLC, high pressure liquid chromatography; MALDI, matrix-assisted laser desorption/ionization; MS, mass spectrometry; PMSF, phenylmethylsulfonyl fluoride; RBP, retinol-binding protein; T4, thyroxine; TLCK, Nα-p-tosyl-l-lysine-chloromethyl ketone; TPCK, Nα-p-tosyl-l-phenylalanine-chloromethyl ketone; wt, wild-type. is a plasma protein of four identical subunits of ∼14 kDa (1Blake C.C.F. Geisow M.J. Oatley S.J. J. Mol. Biol. 1978; 121: 339-356Crossref PubMed Scopus (717) Google Scholar) that is mainly synthesized by the liver and the choroid plexus of the brain (2Dickson P.W. Howlett G.J. Schreiber G. J. Biol. Chem. 1985; 260: 8214-8219Abstract Full Text PDF PubMed Google Scholar). Under physiological conditions, TTR functions as a carrier for both thyroxine (T4) and retinol (vitamin A), in the latter case through binding to the retinol-binding protein (RBP) (3Monaco H.L. Biochim. Biophys. Acta. 2000; 1482: 65-72Crossref PubMed Scopus (149) Google Scholar). We have determined previously that apolipoprotein AI (apoA-I) is also a TTR ligand; physiologically, a fraction of plasma TTR circulates in high density lipoproteins (HDLs) through binding to apoA-I (4Sousa M.M. Berglund L. Saraiva M.J. J. Lipid Res. 2000; 41: 58-65Abstract Full Text Full Text PDF PubMed Google Scholar), its major protein component. The physiological meaning of this interaction remains to be explained, but it first suggested that it might be relevant in physiological conditions, namely in lipid and/or TTR metabolism. Previous evidence suggested that TTR and lipoprotein biology might be related. In the kidney, megalin, a member of the lipoprotein receptor family, is responsible for TTR tubular reabsorption (5Sousa M.M. Norden A.G.W. Jacobsen C. Willnow T.E. Christensen E.I. Thakker R.V. Verroust P.J. Moestrup S.K. Saraiva M.J. J. Biol. Chem. 2000; 275: 38176-38181Abstract Full Text Full Text PDF PubMed Scopus (100) Google Scholar). Furthermore, TTR uptake by the liver (its major site of degradation) is sensitive to the receptor-associated protein, an inhibitor of uptake of all the ligands of the lipoprotein receptor family (6Sousa M.M. Saraiva M.J. J. Biol. Chem. 2001; 276: 14420-14425Abstract Full Text Full Text PDF PubMed Scopus (56) Google Scholar). Several point mutations in TTR have been linked to the occurrence of TTR-related amyloidosis (ATTR), a disorder that is characterized by the extracellular systemic deposition of mutated or wild-type (wt) TTR as amyloid fibrils (7Saraiva M.J.M. Birken S. Costa P.P. Goodman D.S. J. Clin. Investig. 1984; 74: 104-119Crossref PubMed Google Scholar, 8Cornwell I.I.I. Sletten K. Jonhansson B. Westermark P. Biochem. Biophys. Res. Commun. 1988; 154: 648-653Crossref PubMed Scopus (137) Google Scholar), leading to organ dysfunction and death. The mechanisms by which soluble proteins self-assemble into a fibrillary structure are unknown. Proteolysis has been thought to play an important role in most types of amyloidoses; in several cases, an amyloid peptide is generated by proteolysis of the corresponding protein precursor (9Kisilevsky R. J. Struct. Biol. 2000; 130: 99-108Crossref PubMed Scopus (120) Google Scholar, 10Schormann N. Murrell J.R. Benson M.D. Amyloid. 1998; 5: 175-187Crossref PubMed Scopus (54) Google Scholar). C-terminal TTR peptides with proteolysis occurring between amino acid residues 42 and 59, in addition to intact protein, have been found in amyloid fibrils of some ATTR patients (11Gustavsson A. Jahr H. Tobiassen R. Jacobson D.R. Sletten K. Westermark P. Lab. Investig. 1995; 73: 703-708PubMed Google Scholar). This raised the hypothesis that proteolysis could trigger fibril formation. Amyloidogenic variants of apoA-I have also been reported (12Walsh M.T. Am. J. Pathol. 1999; 154: 11-14Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar). ApoA-I, a 243-amino acid protein, is synthesized by the liver and plays a key role in the formation, metabolism and catabolism of HDL cholesterol esters. Numerous attempts have been made to determine the arrangement of the amphipathic helices of apoA-I in nascent HDL discs, as they appear to be a critical intermediate in reverse cholesterol transport; however, the tertiary arrangement of apoA-I molecules on HDL particles is not defined yet. In apoA-I-related amyloidosis, amyloid fibrils are characterized by deposition of N-terminal fragments of variable length in the mutated protein (12Walsh M.T. Am. J. Pathol. 1999; 154: 11-14Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar). Interestingly we identified an amyloidogenic variant of apoA-I, L178H, where fibrils presented both mutated apoA-I and wt TTR that co-localized in amyloid deposits as seen by immunohistochemistry and analysis of extracted fibrils (13de Sousa M.M. Vital C. Ostler D. Fernandes R. Pouget-Abadie J. Carles D. Saraiva M.J. Am. J. Pathol. 2000; 156: 1911-1917Abstract Full Text Full Text PDF PubMed Scopus (88) Google Scholar). This data further suggested that the interaction between apoA-I and TTR might be relevant not only physiologically but also in pathological conditions. In this report we further investigated the apoAI-TTR interaction and verified that TTR is able to process apoA-I proteolytically. Proteins and Protease Inhibitors—Recombinant TTR was produced in Escherichia coli D1210 transformed with pINTR plasmid carrying TTR cDNA (14Furuya H. Nakazato M. Saraiva M.J. Costa S.P. Sasaki H. Matsuo H. Goto I. Sakaki Y. Biochem. Biophys. Res. Commun. 1989; 163: 851-859Crossref PubMed Scopus (12) Google Scholar). The protein was isolated and purified as described previously (15Almeida M.R. Damas A.M. Lans M.C. Brower A. Saraiva M.J. Endocrine. 1997; 6: 309-315Crossref PubMed Scopus (85) Google Scholar). Briefly, after osmotic shock of bacteria, protein extracts were run on diethylaminoethyl (DEAE)-cellulose (Whatman) ion exchange chromatography, dialyzed, lyophilized, and isolated in native preparative Prosieve agarose (FMC Corp.) gel electrophoresis following the supplier's instructions. After electrophoresis, the TTR band was excised and electroeluted in an Elutrap system (Schleicher & Schuell) in 38 mm glycine and 5 mm Tris, pH 8.3, overnight at 50 V (4 °C). A final purification by high pressure liquid chromatography (HPLC) was performed on a Protein Pak 125 column (Waters) coupled to a high precision pump (P-302) and a halocrome-280 UV detector (Gilson), using as eluent 200 mm sodium phosphate buffer, pH 7, at a flow rate of 0.4 ml/min, and 400-μl fractions were collected. Protein standards used for calibration were bovine serum albumin (67 kDa), ovalbumin (43 kDa), chymotrypsinogen A (25 kDa), and lysozyme (14 kDa). Serum TTR was purified as described previously (15Almeida M.R. Damas A.M. Lans M.C. Brower A. Saraiva M.J. Endocrine. 1997; 6: 309-315Crossref PubMed Scopus (85) Google Scholar). Briefly, plasma was dialyzed against 77 mm NaCl and 50 mm phosphate buffer, pH 7.6, and run on a DEAE-cellulose ion exchange column, after which protein fractions were dialyzed, lyophilized, and chromatographed on a blue Sepharose column (Amersham Biosciences). Plasma TTR was isolated by preparative electrophoresis, followed by electroelution and HPLC as described above for recombinant TTR. Serum RBP was isolated by affinity in a TTR column and saturated with 3.3 mg/ml all-trans retinol (Sigma) in ethanol as follows: (i) 25 μl of all-trans-retinol were incubated with 800 μl of RBP (1 mg/ml) at 37 °C in the dark for 1 h; and (ii) excess retinol was separated from RBP by gel filtration in 10-ml Biogel P-6 DG columns (Bio-Rad). Recombinant ApoA-I, α2-macroglobulin, and diisopropyl fluorophosphate (DFP) were from Calbiochem. Phenylmethanesulfonyl fluoride (PMSF) and T4 were from Sigma. Pefabloc, Pefabloc SC Plus, chymostatin, Nα-p-tosyl-l-phenylalanine-chloromethyl ketone (TPCK), Nα-p-tosyl-l-lysine-chloromethyl ketone (TLCK), antipain, aprotinin, phosphoramidon, E64, EDTA, bestatin, pepstatin, and leupeptin were from Roche Applied Science. TTR Proteolysis Assay Using ApoA-I as Substrate—TTR and apoA-I at an equimolar ratio were incubated in 50 mm Tris, pH 6.8, at 37 °C for 3 h unless stated otherwise. After incubation, reactions were run on 15% SDS-PAGE gels and visualized by Coomassie Blue staining (0.125% Coomassie Blue reagent, 50% methanol, and 10% acetic acid). For inhibition assays, TTR was pre-incubated with each of the protease inhibitors (either 4 mm Pefabloc or 4 mm Pefabloc Plus, 10 mm EDTA, 10 μm E-64, 10 μm phosphoramidon, 10 μm bestatin, 0.3 μm aprotinin, 100 μm TPCK, 100 μm TLCK, 100 μm chymostatin, 100 μm leupeptin, 100 μm antipain, 1 mm PMSF, 100 μm DFP, 1 μm pepstatin, and α2-macroglobulin equimolar with TTR) for 30 min at 37 °C before the addition of apoA-I. Analysis of ApoA-I Cleavage Products—For N-terminal sequencing of cleavage products, the apoAI-TTR reaction was run on a 15% SDS-PAGE gel, transferred to a polyvinylidene fluoride membrane (Amersham Biosciences), and stained with Coomassie Blue for 5 min. Pieces of membrane containing apoA-I fragments were excised, and N-terminal sequencing was performed on an Applied Biosystems model 494 protein sequencer. For matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS), apoA-I cleavage products were cut from a 15% SDS-PAGE gel stained with Coomassie Blue. Gel bands were reduced by incubation with 0.01 m dithiothreitol and 0.1 m Tris (pH 8.5) alkylated with 0.015 m iodoacetamide and 0.1 m Tris (pH 8.5) and prepared for trypsin digestion by washing once with 0.05 m Tris (pH 8.5) and 25% acetonitrile and twice with 0.05 m Tris (pH 8.5) and 50% acetonitrile. After destaining, gel bands were digested with trypsin and analyzed on a Perspective Voyager DE-RP mass spectrometer in a linear mode (16Henzel W.J. Billeci T.M. Stults J.T. Wong S.C. Grimley C. Watanabe C. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 5011-5015Crossref PubMed Scopus (1189) Google Scholar). For C-terminal sequencing of the apoA-I fragments, 200 μg TTR and 100 μg of apoA-I were incubated in 50 mm Tris, pH 6.8, overnight at 37 °C, and the reaction was run on a 15% SDS-PAGE gel, transferred to a polyvinylidene fluoride membrane, and stained with Coomassie Blue. Pieces of membrane containing apoA-I fragments were excised, and C-terminal sequencing was performed on an Applied Biosystems model 494 protein sequencer (17Boyd V.L. Bozzini M. Zon G. Noble R.L. Mattaliano R.J. Anal. Biochem. 1992; 206: 344-352Crossref PubMed Scopus (79) Google Scholar). SDS-PAGE Zymography—12% SDS-polyacrylamide gels containing casein (Bio-Rad) were used to identify caseinolytic activity of TTR. 25 μg of recombinant TTR were run per lane. After electrophoresis, gels were incubated in 2.5% Triton X-100 (renaturation buffer; Bio-Rad) for 30 min and subsequently overnight at 37 °C in 50 mm Tris, 200 mm NaCl, 5 mm CaCl2, and 0.02% Brij 35 (development buffer; Bio-Rad). Gels were then stained with 0.5% Coomassie Blue in 40% methanol and 10% acetic acid for 2 h and destained in 40% methanol and 10% acetic acid for 1 h. For Western blot analysis, proteins were transferred to a nitrocellulose membrane (Amersham Biosciences), blocked with 5% blocking buffer (5% nonfat dried milk in phosphate buffer saline), incubated for 1 h at room temperature with rabbit polyclonal anti-TTR (DAKO; 1:2000 in blocking buffer), and incubated for 1 h at room temperature with anti-rabbit IgG conjugated with horseradish peroxidase (The Binding Site; 1:5000 in blocking buffer). The immunoblot was developed using 3,3′-diaminobenzidine (Sigma) as substrate. Fluorometric Assessment of Proteolysis—TTR proteolytic activity was tested with a fluorogenic peptide (Abz-ESFKVS-EDDnp; Global Peptide) encompassing the sequence of apoA-I cleaved by TTR. Abz-ESFKVS-EDDnp is an internally quenched fluorescent peptide in which Abz (ortho-aminobenzoic acid) is the fluorescent donor and EDDnp [N-(ethylenediamine)-2,4-dinitrophenyl amide] is the fluorescent quencher. A stock solution of peptide substrate was prepared by dissolving the peptide in 50% dimethyl sulfoxide (Sigma) to a final concentration of 1 mm. TTR was added to the substrate in an equimolar ratio (5 μm) at a final volume of 100 μl of reaction buffer (50 mm Tris, pH 6.8). Hydrolysis of the fluorogenic substrate was monitored by measuring fluorescence at λem = 420 nm and λex = 320 nm in an fmax plate reader (Molecular Devices). The kinetics of the reaction was followed for 3 h at 37 °C. To convert relative fluorescence units (RFU) into nanomoles of cleaved substrate, a calibration curve was obtained from the total cleavage of the fluorogenic peptide with chymotrypsin (which is also able to cleave Abz-ESFKVS-EDDnp) by incubating 1 nmol of Abz-ESFKVS-EDDnp substrate with 1 unit of chymotrypsin in a final volume of 200 μl of reaction buffer overnight at 37 °C; serial dilutions ranging from 0.005 to 1 nmol of cleaved peptide substrate were measured at λem = 420 nm and λex = 320 nm. Km was determined according to Michaelis-Menten using concentrations of substrate ranging from 0.5 to 100 μm and 5 μm of TTR. The optimum pH for TTR activity was determined in 50 mm Tris with pH values ranging from 3 to 9. TTR complexed with RBP was obtained by incubation in a 1:4 (TTR/RBP) molar ratio for 1 h at 37 °C in the dark. Complex formation between TTR and T4 was performed according to Almeida et al. (15Almeida M.R. Damas A.M. Lans M.C. Brower A. Saraiva M.J. Endocrine. 1997; 6: 309-315Crossref PubMed Scopus (85) Google Scholar). After ligand binding, TTR activity was tested as described above. As a control for the effect of TTR ligands, chymotrypsin activity was tested in the presence of RBP or T4 under the same conditions used for TTR. Cellular Assays—Cell lines were propagated in 12-well plates in monolayers and maintained at 37 °C in a 95% humidified atmosphere and 5% CO2. Cells were grown in Dulbecco's modified Eagle's media (Invitrogen) supplemented with 10% fetal bovine serum (Sigma), 50 units/ml penicillin, and 50 μg/ml streptomycin (complete medium; Invitrogen). RN22 (rat schwannoma cell line) and FAO (rat hepatoma) cell lines were from the American Type Culture Collection. SAHep (human hepatoma without TTR expression) and Huh7 (human hepatoma with high levels of TTR expression) cell lines were kindly provided by Dr. João Monjardino (Imperial College, London, UK). RN22 cell lines were stably co-transfected with human wt TTR cDNA, subcloned in the p169ZT plasmid, which contains the metallothionein inducible promoter (18Sousa M.M. Fernandes R. Palha J.A. Taboada A. Vieira P. Saraiva M.J. Am. J. Pathol. 2002; 161: 1935-1948Abstract Full Text Full Text PDF PubMed Scopus (92) Google Scholar), and with a plasmid conferring resistance to neomycin (pL2Neo, kindly provided by Dr. Paulo Vieira, Institut Pasteur, Paris, France) following the CaPO4-DNA precipitate method (19Sambrook J. Fritsch E.F. Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd Ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY1989: 16.33-16.36Google Scholar). RN22 cell lines stably transfected with human wt TTR cDNA were named RN22 wt. SAHep and FAO cell lines were co-transfected with a construct carrying human wt TTR cDNA under the control of the mouse endogenous TTR promoter (pGEM-2 pTTR exV3, a kind gift from Dr. Robert Costa, University of Illinois, Chicago) and the pL2Neo plasmid using LipofectAMINE (Invitrogen) according to the manufacturer's recommendations. Briefly, 3 × 105 cells were plated in 100-mm tissue culture plates 1 day before transfection and exposed to a mixture of LipofectAMINE and plasmid DNA for 5 h, after which Dulbecco's modified Eagle's medium supplemented with 20% fetal bovine serum was added. Resistant colonies were selected in medium supplemented with G418 (1 mg/ml, Sigma). SAHep and FAO cell lines stably transfected with human wt TTR cDNA were termed SAHep wt and FAO wt, respectively. Huh7 and SAHep cells were grown until ∼80% confluence, after which the culture medium was removed and replaced by Dulbecco's modified Eagle's medium without fetal bovine serum supplemented with 40 μg/ml DQ gelatin (Molecular Probes). DQ gelatin is an intramolecularly quenched substrate heavily labeled with fluorescein, which is used as a substrate for several proteases. Proteolysis of DQ-gelatin yields fluorescent cleaved gelatin-fluorescein peptides; therefore, the localization of fluorescence indicates the sites of net proteolytic activity. For inhibition assays, either 1 mg/ml Pefabloc or 2 μg/ml aprotinin were added to the culture medium. Cells were observed 24 h later on a fluorescence microscope (Auxiovert 200 m, Zeiss). Images were acquired with a coupled digital camera (Zeiss) using either transmission or the fluorescein isothiocyanate channel (λem = 515 nm and λex = 495 nm). In cellular assays using Abz-ESFKVS-EDDnp, ∼80% confluent RN22, RN22 wt, FAO, FAO wt, SAHep, and SAHep wt cells were incubated with 4 nmol of Abz-ESFKVS-EDDnp at 37 °C for 24 h. To assess the effect of RBP, a molar excess of this TTR ligand was added to the culture medium for 1 h at 37 °C before the addition of Abz-ESFKVS-EDDnp. Fluorometric assessment of proteolysis was performed by using 100 μl of each conditioned medium and measuring fluorescence at λem = 420 nm and λex = 320 nm in a Molecular Devices fmax plate reader. After removing conditioned media, cells were treated with 0.1 m NaOH until complete lysis and total protein quantification was performed by the Bradford method (Bio-Rad) using bovine serum albumin ranging from 50 to 200 μg/ml as standard. TTR expression in each cell line was assessed by a TTR quantitative enzyme-linked immunoreactive assay (ELISA). 96-well plates (Maxisorp-Nunc) were coated overnight at 4 °C with polyclonal anti-rabbit TTR (DAKO; 1:500 in 0.1 m carbonate buffer) and blocked with 5% skim milk in phosphate-buffered saline. 100 μl of each conditioned media were applied for 1 h at room temperature. Development was performed using peroxidase-conjugated anti-human TTR (1:500 in phosphate buffered saline and 0.05% Tween 20) and 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)/H2O2. TTR concentration was calculated from a standard curve ranging from 5 to 200 ng/ml. Proteolytic activity was defined as 1 nanomole of cleaved substrate per microgram of total cellular protein in each cell line. Three independent experiments were performed, and results depict a representative experiment. Identification of TTR Proteolytic Activity—We have established previously that a fraction of plasma TTR circulates in HDLs through binding to apoA-I (4Sousa M.M. Berglund L. Saraiva M.J. J. Lipid Res. 2000; 41: 58-65Abstract Full Text Full Text PDF PubMed Google Scholar). To further address the nature of the interaction between TTR and apoA-I, we tried to obtain a complex of the two proteins by incubation at 37 °C and physiological pH. By SDS-PAGE analysis, we observed that apoA-I was cleaved in the presence of recombinant TTR (Fig. 1A, lane 4). A major apoA-I fragment of ∼26 kDa was seen; however, with higher incubation times, two extra apoA-I fragments could be observed (data not shown). This was the first evidence suggesting that TTR might be a cryptic protease able to use apoA-I as a substrate. To confirm this hypothesis, incubation of apoA-I with plasma TTR was performed, and the same pattern of SDS-PAGE migration was obtained (Fig. 1A, lane 5). The fact that incubation of apoA-I with either recombinant TTR or plasma TTR from different sources generated the same pattern of apoA-I degradation (Fig. 1A) pointed to a TTR-intrinsic proteolytic activity and argued against the presence of a contaminant protease in the preparation. TTR preparations presented decreased proteolytic activity or completely lost activity with repeated freeze-thawing cycles. LCQ/MS/MS, a powerful tool for identifying protein contaminants in preparations, was performed in one of the recombinant TTR preparations and only TTR-related peaks were observed (data not shown), further suggesting that TTR itself is a novel cryptic protease. To further verify the ability of TTR to act as a protease, we used casein zymography because casein is well known to act as a universal protease substrate (20Jobin M.C. Grenier D. FEMS Microbiol. Lett. 2003; 220: 113-119Crossref PubMed Scopus (41) Google Scholar). When TTR was run on casein zymogram gels, one major band of degraded casein was visualized (Fig. 1B, arrow). To ascertain whether TTR was responsible for the appearance of the unstained, degraded casein band, we performed anti-TTR Western analysis of zymograms, which showed that the band with caseinolytic activity corresponded in fact to TTR (Fig. 1B). Serine Protease Inhibitors Block ApoA-I Cleavage by TTR—To characterize the nature of the proteolytic activity of TTR, we used a spectrum of protease inhibitors and tested their ability to block apoA-I cleavage by TTR. α2-macroglobulin (α2M), an inhibitor of all classes of proteases, completely inhibited proteolysis of apoA-I (data not shown); the serine protease inhibitors Pefabloc, PMSF, and DFP abolished apoA-I processing by TTR, whereas inhibitors of other protease classes were without effect (Fig. 2). Chymostatin and TPCK, inhibitors of chymotrypsin-like serine proteases, were also able to block TTR activity (Fig. 2). These data suggested that TTR has a chymotrypsin-like serine protease activity. Identification of the Cleavage Site on ApoA-I—To establish the cleavage site in apoA-I, we started by performing N-terminal sequencing of apoA-I fragments generated upon incubation with TTR. As the identified N terminus of the major proteolytic fragment of apoA-I was intact, we concluded that cleavage was occurring in the C terminus of the protein, and we subsequently analyzed the major apoA-I proteolytic fragment by MALDI-MS. A C-terminally deleted apoA-I was identified, presenting MS peaks spanning from amino acid residues 1 to 215 of the protein (Table I). As can be seen by comparison of the MALDI-MS of tryptic peptides derived from full-length apoA-I and apoA-I digested by TTR (Table I), cleavage by TTR occurred between amino acid residues 216 and 226 of apoA-I, because the 216-226 peptide peak, corresponding to the sequence QGLLPVLESFK, was missing in the tryptic MS analysis of apoA-I digested by TTR (Table I). To determine the exact cleavage site, the highest molecular weight fragment of apoA-I digested by TTR was subjected to C-terminal sequencing. This analysis identified the cleavage site in apoA-I as being after Phe-225. For subsequent proteolytic assays, a fluorogenic peptide corresponding to amino acid residues 223-228 of apoA-I (Abz-ESFKVS-EDDnp), which encompasses the sequence that is being cleaved by TTR, was used.Table IMS analysis of tryptic peptides derived from full-length apoA-I and TTR-digested apoA-IPositionSequenceFull-length apoA-Ia+, present; −, absent.TTR-digested apoA-Ia+, present; −, absent.1-10DEPPQSPWDR++1-12DEPPQSPWDRVK++13-23DLATVYVDVLK++13-40DLATVYVDVLKDSGRDYVSQFEGSALGK++24-40DSGRDYVSQFEGSALGK++28-40DYVSQFEGSALGK++46-59LLDNWDSVTSTFSK++60-77LREQLGPVTQEFWDNLEK++60-83LREQLGPVTQEFWDNLEKETEGLR++62-77EQLGPVTQEFWDNLEK++62-83EQLGPVTQEFWDNLEKETEGLR++97-106VQPYLDDFQK++97-107VQPYLDDFQKK++107-116KWQEEMELYRQK++108-116WQEEMELYRQK++117-131QKVEPLRAELQEGAR++119-131VEPLRAELQEGAR++119-133VEPLRAELQEGARQK++132-140QKLHELQEK++141-149LSPLGEEMR++141-151LSPLGEEMRDR++154-160ARAHVDAL++154-173ARAHVDALRTHLAPYSDELRQR++161-171THLAPYSDELR++189-195LAEYHAK++207-215AKPALEDLR++216-226QGLLPVLESFK+−216-239QGLLPVLESFKVSFLSALEEYTKK+−227-238VSFLSALEEYTK+−227-239VSFLSALEEYTKK+−a +, present; −, absent. Open table in a new tab Hydrolysis of the Fluorogenic Peptide Abz-ESFKVS-EDDnp by TTR—Different TTR preparations available in our laboratory were used to test the proteolytic cleavage of the Abz-ESFKVS-EDDnp fluorogenic peptide. All of the recombinant batches of protein, as well as the TTR isolated from plasma, retained the ability to cleave the fluorogenic peptide. In an attempt to establish a possible correlation between proteolysis and pathological or physiological processes, the preparations used included both wt or different TTR mutations related either to amyloidogenesis or to structural mutants with biological implications such as T4 binding. The following TTR mutants were used: (i) V30M, the most frequent mutation related to ATTR; (ii) L55P, which is associated with the most aggressive form of ATTR; (iii) T119M, a nonpathogenic variant shown to have a protective effect on the clinical evolution of the disease; and (iv) E92C and S117C, mutants designed with the purpose of stabilizing the dimer/tetramer interactions. TTR activity was apparently independent from these constraints (data not shown), suggesting that the conformational changes occurring either on amyloidogenic variants of the protein or in stabilized dimer/tetramer interactions do not compromise proteolytic activity. The optimum pH determined for TTR cleavage was 6.8; the same optimum pH was determined for cleavage of apoA-I (data not shown). The cleavage reaction of the fluorogenic peptide yielded a Km of 29 μm, as determined by Michaelis-Menten kinetics (Fig. 3A). The proteolytic activity of TTR preparations purified by HPLC was tested in each of the eluted fractions in activity assays using Abz-ESFKVS-EDDnp as substrate. The fractions corresponding to TTR elution clearly overlapped with the fractions having proteolytic activity toward Abz-ESFKVS-EDDnp (Fig. 3B), further demonstrating TTR-specific cleavage of the fluorogenic peptide. The putative influence of the major TTR ligands (T4 and RBP) on its proteolytic activity was tested; we observed that, whereas RBP completely inhibited TTR activity, T4 only produced an ∼15% decrease of TTR mediated proteolysis (Fig. 3C). As a control for the effect of TTR ligands in its proteolytic activity, the activity of chymotrypsin in the presence of either RBP or T4 was tested. The activity of chymotrypsin was unaltered by the presence of RBP or T4 (Fig. 3C), therefore showing that the inhibition produced by these ligands is TTR-specific. Assessment of Proteolysis Using Cellular Assays—To assess the ability of TTR to exert its proteolytic activity in cellular assays, we started by comparing the degradation of DQ gelatin by hepatomas without TTR expression (SAHep) with the degradation caused by hepatomas with high levels of TTR expression (Huh7). DQ gelatin is an intramolecularly quenched substrate of gelatinases and several other proteinases (including se
Referência(s)